The stock of Polr Cptl Glbl Hlthcre Grth (LON:PCGH) is a huge mover today! The stock decreased 3.00% or GBX 5.75 on November 24, hitting GBX 185.75. About 178,259 shares traded hands or 122.19% up from the average. Polr Cptl Glbl Hlthcre Grth (LON:PCGH) has risen 6.65% since April 27, 2016 and is uptrending. It has outperformed by 1.24% the S&P500.
The move comes after 8 months negative chart setup for the GBX 223.78 million company. It was reported on Nov, 24 by Barchart.com. We have GBX 172.75 PT which if reached, will make LON:PCGH worth GBX 15.66M less.
More notable recent Polr Cptl Glbl Hlthcre Grth (LON:PCGH) news were published by: Ft.com which released: “Biotech sell-off hurts Woodford trust and specialist funds” on October 15, 2015, also Ft.com with their article: “London develops as global healthcare hub” published on January 31, 2016, Washingtonpost.com published: “US will spend $2.6 trillion less on health care than expected before Obamacare …” on June 21, 2016. More interesting news about Polr Cptl Glbl Hlthcre Grth (LON:PCGH) were released by: Washingtonpost.com and their article: “Americans are shouldering more and more of their health-care costs” published on June 27, 2016 as well as Forbes.com‘s news article titled: “Report: The Future Health Ecosystem Today Provides Look Into Healthcare’s Future” with publication date: February 03, 2016.
Polar Capital Global Healthcare Growth and Income Trust plc is a United Kingdom investment trust company. The company has a market cap of 223.78 million GBP. The Company’s investment objective is to generate capital growth and income by investing in a global portfolio of healthcare stocks. It currently has negative earnings. The Firm seeks to achieve its objective by investing in a diversified global portfolio consisting primarily of listed equities issued by healthcare companies involved in pharmaceuticals, medical services, medical devices and biotechnology.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.